Overview

Stem Cell Market is estimated to register a CAGR 8.8% during the forecast period 2022 to 2028.

Advanced research in the development of biomaterial polymeric systems has resulted in a significant rise in recent years. These systems are instrumental in aiding the survival of stem cells which has boosted the market growth. Furthermore, advancements in the treatment of damaged tissues and diseased organs coupled with an increasing demand for regenerative medicines has propelled the market growth significantly.

The adoption of stem cell has opened new opportunities for applications such as wound healing therapy which has assisted in the further augmentation of the market. The increased supply of biomaterial development used in stem cell transplantation and induced pluripotent stem cells (iPSCs) has revolutionised the stem cell sector. Such innovations allow researchers to create pluripotent stem cells from adult somatic cells which aid in preserving genetic information in these cells thus boosting the market growth.

Based on the type of product, the market is categorised as adult stem cells, human embryonic stem cells, induced pluripotent stem cells and very small embryonic-like stem cells. The adult stem cell segment accounts for the largest market share and is predicted to continue this dominance during the forecast period. This is due to the low contamination risks linked to the minimal requirement of production labour, compatibility with the human body and sub-culturing.

Pharmaceutical companies have profitable opportunities in the stem cell sector by initiating advancements in the identification of leading candidates thus allowing companies to develop novel drugs. Furthermore, extensive research has advanced the analysis of single-cell thus helping study the effects of drugs on cell differentiation. Additionally, the growing dependence of developing entities in cellular systems is projected to help the segment strengthen its market position in the upcoming years.

Technology-wise, the market is bifurcated into cell acquisition, bone marrow harvest, apheresis, umbilical blood cord, cell production, therapeutic cloning, in-vitro fertilization, cell culture, isolation, expansion & sub-culture and cryopreservation. The cell production technology held the largest market share due to the current technological advancements aiming at satisfying the growing needs from different clinical applications. A soaring number of organ replacement approaches coupled with the rising demand for therapeutics has bolstered the market significantly. For instance, approximately 2200 transplant surgeries that were conducted in 2016 across the world were pancreas transplants.

Depending on the type of therapy, the market is fragmented into autologous stem cell therapy and allogeneic stem cell therapy.

Autologous stem cell therapy dominated the market concerning revenue generation in 2018. This is mainly attributed to the consumption of autologous products on a large scale owing to associative high compatibility. Additionally, meta-analytical studies on the effectiveness of autologous therapy for the treatment of lower limb disorders will propel the market further. Many companies are engaged in developing these autologous products for patients with sport-related injuries despite it being scrutinized by multiple government bodies.

Regional Insights:

The Asia Pacific region is projected to attain a remarkable CAGR over the forecast period. Developed economies like Australia, Singapore and Japan are extensively investing in the research and development projects which shall drive the market growth. Asia Pacific countries are likely to lead the rapidly evolving stem cell industry. Commercialization opportunities coupled with favourable regulatory policies bolster the market expansion. Japan, in particular, has initiated regulatory amendments related to regenerative medicine which has attracted international manufacturers to invest massively in the Japanese market.

Key market players include
Stemcell Technologies Inc., Celegene Corp., Osiris Therapeutics Inc., Biotime Inc., Advanced Cell Technology Inc. , Human Longevity Inc., Cynata, Promethera Biosciences, Mesoblast., Celgene Corporation, ReNeuron Group plc, Cytori Therapeutics, Inc., Cryo-Cell International Inc.

Market Segmentation:

By Product

• Adult Stem Cells
o Hematopoietic
o Mesenchymal
o Neural
o Epithelial/Skin
o Others
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic-like Stem Cells

By Application

• Regenerative Medicine
o Neurology
o Orthopaedics
o Oncology
o Haematology
o Cardiovascular and Myocardial Infraction
o Injuries
o Diabetes
o Liver Disorder
o Incontinence
o Others
• Drug Discovery & Development

By Technology

• Cell Acquisition
o Bone Marrow Harvest
o Umbilical Blood Cord
o Apheresis
• Cell Production
o Therapeutic Cloning
o In vitro Fertilization
o Cell Culture
o Isolation
• Cryopreservation
• Expansion and Sub-culture

By Therapy

• Autologous
• Allogenic

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Stem Cell Market Sample Video:

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects for stem cell market
SWOT analysis
Key trends in stem cell regeneration techniques
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the stem cell market by technology, by product, by application, by therapy and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Profiling of companies to evaluate their market shares, strategies, financials and core competencie

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com